City

Chicago (1)

Lishui (1)

Loma Linda (1)

Condition

Nephrogenic Fibrosing Dermopathy (3)

Nephrogenic Systemic Fibrosis (2)

Overall Status

Completed (1)

Recruiting (1)

Terminated (1)

Sign in for free

Phase

phase 4 (2)

Sponsor

Loma Linda University (1)

Northwestern University (1)

The Central Hospital of Lishui City (1)

Collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd. (1)

National Institutes of Health (NIH) (1)

Intervention

gadodiamide (1)

gadoteric acid meglumine salt (1)

plasmapheresis (1)

Study Documents

Intervention Type

drug (1)

procedure (1)

Funder Type

Other (3)

Study Type

Interventional (2)

Observational (1)

nephrogenic fibrosing dermopathy

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Nephrogenic Fibrosing Dermopathy Trial in Lishui (Gadodiamide, Gadoteric Acid Meglumine Salt)

Recruiting

Nephrogenic Fibrosing Dermopathy

Gadodiamide
Gadoteric Acid Meglumine Salt

Lishui, Zhejiang, China

Lishui Central Hospital

Feb 26, 2021

Nephrogenic Systemic Fibrosis: Analysis of Tissue Gadolinium

Completed

Nephrogenic Systemic Fibrosis
Nephrogenic Fibrosing Dermopathy

Chicago, Illinois

Northwestern University Feinberg School of Medicine, Department

Dec 2, 2014

Nephrogenic Fibrosing Dermopathy, Nephrogenic Systemic Fibrosis Trial in Loma Linda (Plasmapheresis)

Terminated

Nephrogenic Fibrosing Dermopathy
Nephrogenic Systemic Fibrosis

Plasmapheresis

Loma Linda, California

Loma Linda University Medical Center

Nov 19, 2014